Dr. Gansert is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1800 Owens St
San Francisco, CA 94158Phone+1 805-630-8670
Summary
- Oncologic drugs development across all platforms and tumor types
Education & Training
- Pepperdine Graziadio School of BusinessMBA, 2021 - 2024
- Ronald Reagan UCLA Medical CenterPost-Doctoral Fellowship, 2003 - 2005
- UCLAPhD, Microbiology, Immunology, and Molecular Genetics, 1998 - 2003
- UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1997 - 2003
- Ronald Reagan UCLA Medical CenterResidency, 1995 - 1998
- Stony Brook University Health Sciences Center School of MedicineClass of 1995
Publications & Presentations
PubMed
- 421 citationsRandomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients...Jason Chesney, Igor Puzanov, Frances A. Collichio, Parminder Singh, Mohammed M. Milhem
Journal of Clinical Oncology. 2017-10-05 - 1662 citationsTalimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced MelanomaRobert H.I. Andtbacka, Howard L. Kaufman, Frances A. Collichio, Thomas Amatruda, Neil Senzer
Journal of Clinical Oncology. 2015-05-26 - 470 citationsErratum: Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy (Cell (2017) 170(6) (1109–1119.e10) (S0092867417309522) (...Antoni Ribas, Reinhard Dummer, Igor Puzanov, Ari M. Vanderwalde, Robert H.I. Andtbacka
Cell. 2018-08-09
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: